The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S’s (NASDAQ:ASND) TransCon hGH (lonapegsomatropin) for the treatment…
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center
Companies Reporting Before The Bell
• 36KR Holdings (NASDAQ:KRKR) is expected to report quarterly loss at $0.11 per share on revenue of $10.82 million.
Companies Reporting Before The Bell
• Royal Bank of Canada (NYSE:RY) is likely to report quarterly earnings at $2.48 per share on revenue of $11.77 billion.
Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts.